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ABSTRACT 22 
Introduction: Kidney fibrosis has shown to be ameliorated through the involvement of cyclic 23 
guanosine monophosphate (cGMP) and its dependent protein kinase I (cGKI). Serelaxin, the 24 
recombinant form of human relaxin-II, increases cGMP levels and has shown beneficial effects on 25 
kidney function in acute heart failure patients. Antifibrotic properties of serelaxin are supposed to be 26 
mediated via relaxin family peptide receptor 1 and subsequently enhanced nitric oxide/ cGMP to 27 
inhibit TGF-β signaling. This study examines the involvement of cGKI in the antifibrotic signaling of 28 
serelaxin.  29 
 30 
Methods and Results: Kidney fibrosis was induced by unilateral ureter obstruction in wildtype 31 
(WT) and cGKI knock-out (KO) mice. After 7 days, renal antifibrotic effects of serelaxin were 32 
assessed. Serelaxin treatment for 7 days significantly increased cGMP in the kidney of WT and 33 
cGKI-KO. In WT, renal fibrosis was reduced through decreased accumulation of collagen1A1, total 34 
collagen and fibronectin. The profibrotic CTGF as well as myofibroblast differentiation were reduced 35 
and matrix metalloproteinases-2 and -9 were positively modulated after treatment. Moreover, Smad2 36 
as well as extracellular signal-regulated kinase 1 (ERK1) phosphorylation were decreased, whereas 37 
phosphodiesterase (PDE) 5a phosphorylation was increased. However, these effects were not 38 
observed in cGKI-KO.  39 
 40 
Conclusion: Antifibrotic renal effects of serelaxin are mediated via cGMP/cGKI to inhibit Smad2- 41 
and ERK1 -dependent TGF-β signaling and increased PDE5a phosphorylation. 42 
 43 
Key words:  Relaxin, serelaxin, cGMP-dependent protein kinase, kidney, interstitial fibrosis, 44 
signaling, nitric oxide 45 
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1. Introduction 47 
Kidney fibrosis is a key contributor to chronic kidney disease (CKD), mainly resulting from diabetes 48 
or hypertension in developed countries. The prevalence of CKD is estimated 7.2% in patients aged 49 
30 years or older.(Zhang and Rothenbacher, 2008) Renal fibrosis is characterized by excessive 50 
accumulation of extracellular matrix (ECM) including collagen and fibronectin. Transforming growth 51 
factor-β (TGF-β) and connective tissue growth factor (CTGF) are profibrotic cytokines which 52 
promote fibroblast to myofibroblast differentiation expressing α-smooth muscle actin (α-SMA). 53 
These cells are predominantly expressed in fibrotic tissue contributing to the deposition of ECM and 54 
modulation of matrix metalloproteinases (MMPs). To prevent or reduce renal fibrotic tissue, the 55 
modulation of cyclic nucleotides, particularly cyclic guanosine monophosphate (cGMP) might be 56 
promising. cGMP has already shown to be increased in kidney fibrosis as well as further increased 57 
through pharmacological intervention for the amelioration of kidney fibrosis and improvement of 58 
renal function.(Wang et al., 2006) Currently, cGMP modulation is achieved by several therapeutic 59 
approaches including nitric oxide (NO) donors and sGC stimulators.(Schlossmann and Schinner, 60 
2012) 61 
Relaxin was firstly described by Hisaw et al. in 1929 due to its antifibrotic effects in the reproductive 62 
system.(Hisaw, 1929) By now, serelaxin showed pleiotropic effects in several experimental and 63 
clinical research, mainly mediated through its G-protein coupled receptor relaxin family peptide 64 
receptor 1 (RXFP1).(Bathgate et al., 2013) Antifibrotic effects involve NO, soluble guanylate cyclase 65 
(sGC) and the downstream mediator cGMP to inhibit TGF-β signaling.(Samuel, 2005;Halls et al., 66 
2015;Wang et al., 2016) Serelaxin – the recombinant form of the naturally occurring human 67 
pregnancy hormone relaxin-II – is a cGMP modulating agent, which is currently being tested in a 68 
phase III clinical trial for acute heart failure. About 18% to 40% of patients with acute heart failure 69 
also experience worsening of renal function during acute decompensation, which adversely affects 70 
prognosis.(Cole et al., 2012) Serelaxin has already shown improved organ function as indicated by 71 
reduced biomarker levels for renal damage after recompensation.(Metra et al., 2013;Teerlink et al., 72 
2013)  73 
Schinner et al.(Schinner et al., 2013) and Cui et al.(Cui et al., 2014) have demonstrated renal 74 
antifibrotic signalling via NO/cGMP and the cGMP-dependent protein kinase I (cGKI) in rodents 75 
after the administration of NO donors and soluble guanylyl cyclase stimulators. However, a possible 76 
role of cGKI in serelaxin’s antifibrotic effect still remains unclear.  77 
Further research is necessary to elucidate downstream mechanisms involved in the RXFP1- 78 
NO/cGMP dependent antifibrotic pathway. The aim of this study was to examine the antifibrotic 79 
signalling pathway of serelaxin in the kidney. We hypothesized that serelaxin’s antifibrotic properties 80 
are mediated through cGKI.  81 
 82 
2. Methods 83 
2.1 Animals 84 
129/Sv-WT and 129/Sv-cGKI-KO mice (Pfeifer et al., 1998) were bred and maintained in the animal 85 
facilities of University of Regensburg. Experiments are conducted according to the guide for the Care 86 
and Use of Laboratory Animals published by the US National Institute of Health. Protocols were 87 
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approved by local authorities for animal research (Regierung der Oberpfalz, Bayern, Germany, #54-88 
2532.1-26/13) and conducted according to German law for animal care.  89 
2.2 UUO and serelaxin treatment 90 
UUO, an established mouse model for chronic renal interstitial fibrosis,(Chevalier et al., 2009) was 91 
performed according to Schinner et al..(Schinner et al., 2013) Kidney tissues of WT and cGKI-KO 92 
mice were divided into 4 groups: mice untreated or treated with serelaxin. Fibrotic tissue was derived 93 
from UUO-obstructed kidney, healthy tissue from contralateral kidney served as control. Serelaxin 94 
was diluted in 20 mM sodium acetate (pH= 5) and administered continuously through osmotic 95 
minipumps (Alzet; model 1007D) immediately after UUO for 7 days (0.5 mg/ kg/ day).  96 
2.3 Tissue preparation  97 
Under isoflurane inhalation kidney tissue was removed after perfusion with 0.9% NaCl 7 days after 98 
UUO. Proteins from kidney tissue were solubilized in 50 mM Tris/ 2% SDS/ phosphatase inhibitor 99 
(PhosSTOP, Roche; 1 tablet/5 ml) / protease inhibitors (leupeptin 0.5 µg/ml, PMSF 300 µM, 100 
benzamidine hydrochlorid 1mM, EDTA 5 mM) for 45 min at 7°C followed by centrifugation at 101 
12400 g, 7°C, 45 min. In supernatants, protein content was determined by modified Lowry 102 
method(Lowry et al., 1951) and stored at -80°C until analysis.  103 
2.4 Western blot analysis 104 
Protein expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ERK1/2, P- ERK1/2, 105 
P-Smad2, P-VASP (Ser 239), GAPDH (antibodies from Cell Signaling, Danvers, USA), TGF-β, 106 
CTGF, PDE5a (antibodies from Santa Cruz Biotechnology, Heidelberg, Germany) and P-PDE5a (Ser 107 
92) (FabGennix, Texas, USA) were assayed by western blotting. After SDS-PAGE proteins were 108 
transferred to PVDF membranes. Donkey anti-goat IgG HRP (santa cruz Biotechnology, Heidelberg, 109 
Germany) and donkey anti-rabbit IgG HRP (Dianova GmbH, Hamburg, Germany) were used as 110 
secondary antibodies. Quantification was performed by ImageLabTM densitometry software (BioRad, 111 
München, Germany). Values were related to corresponding GAPDH values, except P-ERK1/2 is 112 
related to ERK1/2. Change of markers from healthy to fibrotic tissue was compared by values of 113 
fibrotic tissue in relation to healthy tissue, both untreated WT mice. The influence of treatment on 114 
markers was determined only in fibrotic tissue by analyzing values of markers in relation to mean 115 
values of untreated fibrotic WT, which were set as 1.  116 
2.5 Gelatin zymography assay 117 
The activity of MMP2 and MMP9 was determined using gelatin zymography. SDS-PAGE was 118 
performed with a gel containing 0.1% gelatin. After washing (100 mM NaCl and 2.5% Triton X-100 119 
in 50 mM Tris-HCl, pH 7.5) the gel was transferred to a reaction buffer (200 mM NaCl, 0.02% 120 
NaN3, 0,5 µM ZnCl2, 1 mM CaCl2, 2% Triton-X 100, in 50 mM Tris-HCl, pH 7.5) for enzymatic 121 
reaction at 37°C overnight. Gel was stained with Coomassie blue, destained in 10% acetic acid (v/v) 122 
and 30% methanol (v/v) and quantified using Image Lab. MMPs in fibrotic tissue were expressed as 123 
relative values of markers in fibrotic kidneys from untreated WT mice. 124 
2.6 Enzyme linked immunosorbent assays 125 
Serelaxin serum levels were determined using Human Relaxin-2 Quantikine® ELISA (R&D 126 
Systems, Wiesbaden-Nordenstadt, Germany). cGMP levels in kidney tissue using cGMP EIA (IBL-127 
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Cayman, Hamburg, Germany). Measurements were performed according to manufacturer’s 128 
instructions.  129 
2.7 Sirius red/ fast green method for quantitation of collagen 130 
Collagen levels in the kidneys were measured by a modified sirius red/ fast green method (Lopez-De 131 
Leon and Rojkind, 1985), based on selective binding of sirius red to collagen and fast green dye 132 
binding to non-collagen proteins. Sirius red/ fast green staining was calculated as increase (%) of 133 
collagen [ratio collagen/non-protein collagen] after 7 days UUO related to healthy kidney as 134 
described previously.(Schinner et al., 2013)  135 
2.8 Immunohistochemistry 136 
Kidney tissues were cut at 4 µm. Immunohistochemistry and quantification was performed according 137 
to Schinner et al..(Schinner et al., 2013) Primary antibodies are mouse anti-α-SMA (Beckman 138 
Coulter, Krefeld, Germany), rabbit anti-Col1a1 and rabbit anti-fibronectin (Abcam, Cambridge, UK). 139 
Alexa 647-conjugated donkey anti-rabbit and Cy2-conjugated donkey anti-mouse served as 140 
secondary antibodies. For quantification the increase after UUO was related to the healthy kidney. 141 
2.9 Quantitative RT-PCR 142 
 Isolation of total RNAs from kidney tissue, determination using quantitative RT-PCR as well as 143 
calculation was described previously.(Schinner et al., 2013) mRNA levels of αSMA, fibronectin, 144 
Col1a1, MMP2 and MMP9 were detected. 18S rRNA served as housekeeping gene. The ΔΔCT 145 
(cycle threshold) value is calculated from the difference of the corresponding control (C) and 146 
fibrosis-induced kidneys (F) [ΔΔCT = ΔCT (C) – ΔCT (F)]. Then, the ratio of expression (r) was 147 
determined [r = 2ΔΔCT]. 148 
2.10 Serum creatinine 149 
Serum creatinine was determined by a previously published HPLC method with minor 150 
modifications.(Schramm et al., 2014) Serum (10 μl) was mixed with 50 μl perchloric acid to 151 
precipitate proteins. The tube was mixed, kept at 4°C for 15 min, then centrifuged (5 min, 10,800 g). 152 
5 μl of the supernatant was injected into the HPLC apparatus (Prominence LC20 series equipped with 153 
a LC20A photometric detector set at 234 nm; Shimadzu, Duisburg, Germany). Separation was 154 
performed using a Zorbax 300-SCX 5 μm, 150 × 4.6 mm, analytical column (Agilent,Waldbronn, 155 
Germany) and a mobile phase consisting of 5 mM sodium acetate (pH=5.1) / acetonitrile (800 : 200 156 
(v : v)). Creatinine eluted after 6.3-6.5 min at a flow rate of 1.0 ml/ min (column temperature 35°C).  157 
2.11 Statistical analysis  158 
All data are expressed as mean ± SEM. Statistical differences between two means were calculated by 159 
unpaired student`s t-test (two-tailed, confidence interval 95%). Statistical significance was marked by 160 
asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001). n indicates number of animals. For data analysis, 161 
GraphPad Prism, version 6, (GraphPad software, Inc., La Jolla, CA, USA), was used. 162 
 163 
 164 
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3. Results 165 
3.1 Effect of serelaxin on cGMP and cGKI in kidney tissue 166 
Plasma levels of relaxin were determined through serelaxin ELISA in wildtype (WT) and cGKI 167 
knockout (cGKI-KO) mice. In untreated mice serum levels were at 11.4 ± 1.4 pg/ml for WT (n=11) 168 
and at 0.04 ± 0.04 pg/ml for cGKI-KO (n=5). In serelaxin treated mice serum levels increased to 169 
20361 ± 2290 pg/ml for WT (n=14) and 13357 ± 3122 pg/ml for cGKI-KO mice (n=4, not 170 
significantly different for WT and cGKI-KO), which was highly statistically significant compared to 171 
untreated mice (WT: p < 0.001; cGKI-KO: p = 0.0018). 172 
cGMP levels were investigated in kidney tissue. Figure 1 A shows that cGMP was higher in fibrotic 173 
tissue 7 days after unilateral ureteral obstruction (UUO) than in the contralateral kidney (42.8 ± 5.7 174 
pmol/g vs. 25.9 ± 5.2 pmol/g). After serelaxin treatment cGMP levels of fibrotic kidneys further 175 
increased significantly (95.0 ± 12.5 pmol/g). 176 
The activity of cGKI can be determined by quantification of cGKI-specific vasodilator-stimulated 177 
phosphoprotein (VASP) phosphorylation at Serine 239. In Figure 1 B an increase of VASP 178 
phosphorylation was observed after serelaxin treatment, in healthy and in fibrotic WT tissues. The 179 
increase in WT mice, expressed as relative values in kidneys from untreated WT mice, changed from 180 
0.94 ± 0.12 (n=5) to 1.68 ± 0.32 (n=5) after treatment. In cGKI-KO this effect was lacking (0.79 ± 181 
0.22; n=3 vs. 0.86 ± 0.17; n=2).  182 
3.2 Effect of serelaxin on α-SMA in WT- and cGKI-KO kidneys  183 
mRNA of α-SMA, a marker of myofibroblast differentiation,(Nagamoto et al., 2000)  was increased 184 
in both WT and cGKI-KO after UUO. A reduction of mRNA was observed after treatment with 185 
serelaxin in WT, whereas no effect was seen in cGKI-KO after treatment (Figure 2 A). As expected, 186 
in unobstructed renal tissue only vascular smooth muscle cells were immunostained with α-SMA, in 187 
UUO-obstructed kidneys enhanced interstitial expression was observed (data not shown). In WT, α-188 
SMA protein was elevated compared to the contralateral kidney, after serelaxin treatment the 189 
increase was significantly reduced. In cGKI-KO no significant reduction of α-SMA protein 190 
expression through serelaxin was demonstrated (Figure 2 B).  191 
3.3 Effect of serelaxin on ECM accumulation in WT- and cGKI-KO kidneys  192 
Fibronectin and collagen1A1 (Col1A1) are components of ECM, whose gene expressions are 193 
upregulated in fibrosis through TGF-β signaling. mRNA of both genes were elevated in fibrotic WT 194 
kidney 7 days after UUO compared to the contralateral kidney. Fibronectin and Col1A1 mRNA were 195 
reduced through serelaxin in WT (Figure 3 B, Figure 4 A).  Protein expression was strongly elevated 196 
by more than 40% for fibronectin and Col1A1 in both WT and cGKI-KO mice, compared to kidneys 197 
without UUO (for fibronectin, Figure 3 A, C). Significant reduction of both proteins through 198 
serelaxin treatment was observed only in WT after 7 days of treatments. 199 
Protein expression of total collagen was elevated by 21.4% ± 0.99 in fibrotic WT and significantly 200 
decreased through serelaxin treatment to an elevation of 16.6% ± 1.7 compared to unobstructed 201 
kidneys (p=0.0126). In cGKI-KO, effects of serelaxin on ECM accumulation were not observed 202 
(Figure 3 A, C, Figure 4 B, C). 203 
3.4 Regulation of MMPs by serelaxin in WT- and cGKI-KO kidneys  204 
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MMPs are relevant for the degradation of ECM. mRNA of MMP2 was 6.8-fold (±0.58) increased in 205 
fibrotic tissue, whereas MMP9 was not increased in that pathological condition (0.88-fold ± 0.53). 206 
Through serelaxin treatment, only the elevated levels of MMP2 mRNA were significantly decreased 207 
(4.3-fold ± 0.61), no changes were found for MMP9 mRNA after treatment (0.76-fold ± 0.067). 208 
(Figure 5 C, E). Zymography distinguishes between latent and active MMP proteins (Figure 5 A, B). 209 
In WT, latent and active forms of MMP2 were elevated in fibrosis (5.9-fold ± 1.3; 4.2-fold ± 0.84), 210 
protein expression of latent MMP9 was significantly enhanced in fibrotic tissue (3.0-fold ± 0.42), 211 
active form significantly decreased (0.69-fold ± 0.098) compared to contralateral kidneys (n=12, 212 
respectively).  213 
Figure 5 D and F show regulation of MMPs only in fibrotic tissue expressed as relative values of 214 
markers in kidneys from untreated WT mice. Consistent with data from mRNA, latent and active 215 
forms of MMP2 were both significantly reduced through serelaxin treatment in fibrotic kidneys. 216 
Through reduction of latent MMP9 and increase of active MMP9 after treatment physiological 217 
conditions were nearly restored. 218 
The above described effects on MMP2 and MMP9 were not observed in cGKI-KO mice after 219 
treatment (Figure 5 D, F). 220 
3.5 Signaling Molecules in WT- and cGKI-KO kidneys treated with serelaxin  221 
As mentioned above, cGMP levels were elevated through serelaxin and, so far, cGKI-KO mice 222 
showed no antifibrotic effects, which suggested the involvement of the NO/cGMP/cGKI pathway in 223 
the antifibrotic effect of serelaxin. Subsequently, several signaling molecules were analyzed by 224 
western blotting, which are involved in fibrosis. Representative western blots demonstrated 225 
modulation of the selected markers in fibrotic conditions compared to healthy (Figure 6 A).   226 
Downstream to serelaxin, protein expression of phosphorylated extracellular-signal regulated kinase 227 
1/2 (P-ERK1, P-ERK2) was analyzed. P-ERK1 were significantly elevated in kidneys of WT mice 228 
compared to the contralateral after undergoing UUO for 7 days (P-ERK1:1.8-fold ± 0.24; n=7). 229 
cGMP is degraded by phosphodiesterase (PDE) 5a, which is strongly upregulated in fibrosis (6.0-fold 230 
± 1.3; n=10), whereas phosphorylation of PDE5a at the cGMP-dependent phosphorylation site serine 231 
92(Thomas et al., 1990) (0.68-fold ± 0.12; n=7) was decreased. TGF-β is a profibrotic cytokine, that 232 
was 5.3-fold (± 1.1; n=12) elevated in the fibrotic kidneys compared to the contralateral renal WT 233 
tissue. Its downstream profibrotic signaling is dependent on Smad or -independent via ERK1/2 234 
phosphorylation. Both P-Smad2 (1.926 ± 0.2384; n=12) and ERK-1 (see above) were significantly 235 
elevated in fibrotic renal WT tissue. Additionally, further TGF-β transcription genes, e.g. CTGF were 236 
analyzed in this experiment. It was confirmed, that CTGF levels were elevated 3.3-fold (± 0.77; 237 
n=12) in obstructed WT kidneys.  238 
Protein levels of all signaling markers were significantly different in healthy and fibrotic kidney 239 
tissue from WT mice – P-PDE5a was reduced, remaining markers increased in fibrosis.  240 
Figure 6 B illustrates the influence of serelaxin on markers only in fibrotic tissue of WT and cGKI-241 
KO. Values are related to untreated fibrotic WT kidneys, which were set as 1.  242 
The phosphorylation of ERK1 normalized to total ERK1 was significantly reduced in WT through 243 
serelaxin treatment, but not in cGKI-KO. 244 
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eNOS and nNOS were increased in fibrosis, but were not further enhanced after treatment with 245 
serelaxin (data not shown).  246 
The cGMP degrading phosphodiesterase (PDE) 5a is slightly enhanced through serelaxin in WT, and 247 
furthermore serelaxin significantly enhanced phosphorylation of PDE5a, indicating enhanced activity 248 
of PDE5a in fibrosis. The treatment-dependent increase in PDE5a phosphorylation is lacking in 249 
cGKI-KO. TGF-β itself remained unchanged in fibrotic tissue despite serelaxin treatment, but 250 
downstream signaling of TGF-β was affected through treatment. Serelaxin significantly reduced P-251 
Smad2 in WT, but not in cGKI-KO. Signaling via Smad-independent pathway was regulated through 252 
ERK1/2 phosphorylation.(Leask and Abraham, 2004) As mentioned above, ERK1 phosphorylation 253 
was significantly reduced after treatment only in WT kidneys. 254 
 As previously stated, collagen, fibronectin and myofibroblast differentiation (α-SMA) was decreased 255 
(see above). 7 days after UUO continuous infusion of serelaxin decreased CTGF significantly in WT, 256 
but not in cGKI-KO.  257 
3.6 Effect of serelaxin on kidney function of WT- and cGKI-KO mice  258 
Kidney function was measured by serum creatinine levels analyzed 7 days after UUO. Figure 7 259 
shows that serum creatinine increased significantly after UUO, but renal performance improved 260 
significantly through serelaxin treatment by reducing serum creatinine levels from 1.0 mg/l ± 0.049 261 
to 0.80 mg/l ± 0.069 in WT. cGKI-KO did not improve kidney function through serelaxin.   262 
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4. Discussion 263 
In this study, we demonstrated that serelaxin mediated its antifibrotic effects via NO/cGMP/cGKI, to 264 
inhibit TGF-β signaling through Smad- and ERK1-dependent pathways (Figure 8).  265 
Serelaxin modulated remodeling processes on several levels resulting in reduced ECM accumulation. 266 
Samuel et al. (Samuel et al., 2003) demonstrated that relaxin-1 deficient mice developed age-related 267 
fibrosis in the kidney and other organs. Endogenous relaxin was able to reduce early fibrotic changes 268 
in kidney tissue after UUO (Hewitson et al., 2007). Serelaxin administration has already shown renal 269 
antifibrotic effects in models of kidney injury, including renal papillary necrosis (Garber et al., 2001), 270 
antiglomerular basement membrane model (McDonald et al., 2003), spontaneously hypertensive rats 271 
(Lekgabe et al., 2005), models of renal mass reduction (Garber et al., 2003) and UUO (Hewitson et 272 
al., 2010).  273 
In our study renal interstitial fibrosis was induced by UUO for 7 days, a method for rapid 274 
development of interstitial fibrosis with enhanced ECM deposition (Chevalier et al., 2009) In our 275 
experiments, ECM components and ECM producing cells were increased. Signaling pathways were 276 
regulated differently in the fibrotic and unobstructed kidney tissue. TGF-β and CTGF, important 277 
profibrotic cytokines, were markedly elevated in fibrotic kidneys. TGF-β signaling is mediated via 278 
Smad-dependent or independent pathways to induce myofibroblast differentiation and gene 279 
expression of collagens, fibronectin, CTGF, ECM degrading MMPs and several other profibrotic 280 
stimuli (Leask and Abraham, 2004). In accordance with previous work on UUO (Masaki et al., 281 
2003;Pat et al., 2005;Hewitson et al., 2010), in the current experiment both signaling mechanisms are 282 
activated in fibrotic tissues, indicated through enhanced ERK1 as well as Smad2 phosphorylation.  283 
Animals were treated with serelaxin starting immediately after UUO. cGMP was upregulated in 284 
fibrotic tissue and further increased in mice treated with serelaxin, suspecting a cGMP dependent 285 
signaling mechanism for serelaxin. The NO/cGMP signaling pathway has often been demonstrated to 286 
influence remodeling processes in different organs, including the kidney (Wang-Rosenke et al., 287 
2011;Sun et al., 2012;Schinner et al., 2015). Phosphodiesterase inhibitors have already shown their 288 
antifibrotic effects by enhanced cGMP availability (Rodriguez-Iturbe et al., 2005;Bae et al., 2012). 289 
cGKI is involved in the signaling process of serelaxin, as serelaxin treated WT mice caused enhanced 290 
activity of cGKI, indicated by the cGKI specific phosphorylation at Ser239 of VASP and Ser92 of 291 
PDE5 compared to untreated mice. The association of cGKI with antifibrotic effects was already 292 
shown by Schinner et al. (Schinner et al., 2013) and Cui et al. (Cui et al., 2014) in a model of UUO-293 
induced renal fibrosis. This was confirmed in our model for serelaxin signaling, as we observed a 294 
significant antifibrotic and antiremodelling effect indicated by reduced fibronectin, Col1A1, total 295 
collagen and α-SMA in WT. These effects were lacking in the cGKI-KO, suggesting an involvement 296 
of cGKI in the antifibrotic properties of serelaxin in the kidney. As previously observed (Schinner et 297 
al., 2013), fibrosis marker were reduced in non-treated cGKI-KO compared to non-treated WT, 298 
however serelaxin treatment did not decrease fibrosis marker in cGKI-KO. 299 
 300 
Serelaxin mainly realizes its antifibrotic effects via the relaxin receptor RXFP1, which is present or 301 
expressed in the kidney (Hsu et al., 2002;Halls et al., 2015) as well as in rat renal fibroblasts and 302 
myofibroblasts in vitro (Masterson et al., 2004) and in vivo (Mookerjee et al., 2009). The effect of 303 
RXFP1 on the enhancement of NO still remains unclear. It is discussed, that it signals through nNOS 304 
to enhance NO/cGMP in myofibroblasts (Mookerjee et al., 2009;Chow et al., 2012) without the 305 
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involvement of eNOS. eNOS appears to have a more significant role in the arterial vasodilatory 306 
effect (McGuane et al., 2011) of serelaxin than in the antifibrotic. However eNOS as well as nNOS 307 
were not increased in our experiment, this does not exclude a role of eNOS or nNOS in the protective 308 
effect of serelaxin as the interplay of the diverse NOS isoforms in the suppression against interstitial 309 
renal fibrosis was previously observed (Morisada et al., 2010). Changes in the expression levels do 310 
not reveal the alterations in the activity of these enzymes, e.g. an altered intracellular calcium 311 
concentration would change the activity of the calcium-dependent eNOS and nNOS. The inhibition 312 
of phosphodiesterases, e.g. the cGMP specific PDE5a, also augments cGMP,. However, PDE5a was 313 
strongly enhanced in fibrosis, the phosphorylation of PDE5a at the cGKI-specific phosphorylation 314 
site serine 92 (Thomas et al., 1990) was additionally strongly upregulated after treatment. The 315 
phosphorylation implicates increased enzyme activity as well as augmented affinity of cGMP to 316 
allosteric binding sites (Rybalkin et al., 2002;Francis et al., 2010) suggesting an autoregulatory 317 
feedback mechanism. Due to the cGKI-specific phosphorylation, no effect of serelaxin on PDE5a 318 
phosphorylation was observed in cGKI-KO.   319 
There is evidence, that TGF-β protein levels are reduced in vivo through serelaxin treatment (Garber 320 
et al., 2001). But consistent with published data from Hewitson et al. (Hewitson et al., 2010), we 321 
confirmed that serelaxin has no influence on TGF-β1 protein levels in kidney tissue in vivo. Most 322 
important TGF-β effects are regulated through phosphorylation of Smad proteins (Massague, 1998) 323 
or enhanced ERK1/2 signaling (Inoki et al., 2000). Suzuki et al. (Suzuki et al., 2004) as well as Piek 324 
et al. (Piek et al., 2001) have shown, that fibronectin synthesis is regulated via the TGF-β dependent 325 
ERK1/2 signaling pathway. Consistent with previous publications (Mookerjee et al., 2009;Chow et 326 
al., 2014;Wang et al., 2016) we found reduced Smad2 phosphorylation through serelaxin treatment to 327 
abrogate ECM accumulation and myofibroblast differentiation. TGF-β dependent ERK signaling was 328 
also inhibited by reduced phosphorylation of ERK1. As no effects of reduced Smad2 or ERK1 329 
phosphorylation were observed in the cGKI-KO, we suspect the involvement of cGKI in the 330 
suppression of TGF-β signaling through serelaxin. The inhibition of ERK1 phosphorylation through 331 
cGMP is in accordance to previous reports (Yeh et al., 2010;Beyer et al., 2015).  However, in 332 
cultured rat renal myofibroblasts ERK1/2 phosphorylation was enhanced (Mookerjee et al., 333 
2009;Chow et al., 2012) and, in contrary, in human renal fibroblasts no influence on ERK1/2 334 
phosphorylation was observed via serelaxin treatment (Heeg et al., 2005). Species and cell-specific 335 
changes may explain different regulations. 336 
The gelatinases MMP2 and MMP9 are ECM-degrading enzymes involved in the remodeling 337 
processes of the kidney, but their role is very complex. They are differently regulated in published 338 
work (Heeg et al., 2005;Hewitson et al., 2007;Hewitson et al., 2010;Chow et al., 2012). Upregulation 339 
increases the degradation of ECM, but on the other hand they also activate TGF-β (Abreu et al., 340 
2002) and increase the degradation of collagen IV, which is mainly included in the basement 341 
membrane and therefore favours EMT (Ronco et al., 2007).  342 
MMP2 was strongly upregulated in fibrotic kidney, whereas MMP9 was unchanged in this 343 
pathological condition. Consistent with the current work, in rodents after UUO elevated MMP2 344 
levels (Sharma et al., 1995) and decreased MMP9 activity (Gonzalez-Avila et al., 1998) were found. 345 
MMP2 gene expression was shown to be increased through Smad2-dependent TGF-β signaling (Piek 346 
et al., 2001). Through serelaxin treatment both latent and active MMP2 were decreased, which might 347 
be explained through reduced phosphorylation of Smad2. The activity of MMP9 was increased. 348 
Hewitson et al. (Hewitson et al., 2010) showed similar results 9 days after UUO, where MMP2 349 
correlated with disease severity. The regulation of MMP2 and MMP9 is assumed to be dependent on 350 
cGKI, as cGKI-KO mice had no treatment dependent MMP regulation. 351 
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CTGF is an early downstream gene of TGF-β, which augments fibrotic effects by directly 352 
potentiating TGF-β effects and inhibiting the renoprotective BMP7 signaling. Furthermore it interacts 353 
with different growth factors and ECM components, to modify their functions or turnovers (Lee et 354 
al., 2015). But most of the signaling mechanisms of CTGF remain unknown. Consistent with our 355 
results, Yokoi et al. (Yokoi et al., 2004) demonstrated increased CTGF levels in rats 7 days after 356 
UUO and improved kidney fibrosis through antisense oligonucleotide treatment. The reduction of 357 
CTGF protein levels is supposed to be mediated through cGKI, as no effects were observed in the 358 
cGKI-KO mice in our study. Nevertheless, data from TGF-β stimulated rat renal cortical fibroblasts 359 
showed that serelaxin had no influence on mRNA levels of CTGF (Masterson et al., 2004).  360 
Kidney function was estimated through measurement of serum creatinine levels using HPLC method. 361 
In accordance with our results, Honma et al. (Honma et al., 2014) also showed significantly 362 
increased serum levels in mice 7 days after UUO. Through the treatment of serelaxin a significant 363 
improvement of kidney function, estimated by decreased serum creatinine levels, was observed in our 364 
experiments as well as in previous experiments in RLX-/- mice (Samuel et al., 2004) and a 365 
antiglomerular basement membrane model (McDonald et al., 2003), when treated with serelaxin. 366 
Whether this increase is due to increased renal plasma flow and glomerular filtration rate (Danielson 367 
et al., 2006) of the contralateral kidney or due to structural changes in the obstructed kidney remains 368 
unclear.  369 
We conclude, that serelaxin signals via RXFP1 and the increase of NO/cGMP and inhibits Smad- and 370 
ERK1-dependent TGF-β signaling through cGKI. cGKI is additionally involved in PDE5a-371 
phosphorylation for the autoregulation of cGMP-dependent effects. Our results identify serelaxin as 372 
antifibrotic agent and broaden the understanding of its signaling process involving cGMP/cGKI. 373 
Further elucidation of the serelaxin signaling pathways will be important for its possible applicability 374 
in the treatment of chronic kidney diseases. 375 
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